BI breathes easy after Spiriva trumps LABAs in old school German HTA
This article was originally published in Scrip
Boehringer Ingelheim's top selling drug, Spiriva (tiotropium) offers additional benefit compared to placebo and long-acting beta-2 agonists (LABAs), says a report from IQWiG, Germany's Institute of Quality and Efficiency in Healthcare. The findings mark a more positive endorsement of the drug than the institute's previous report published in November, which concluded that Spiriva offered additional benefit in comparison only to one LABA, salmeterol.
You may also be interested in...
Softening provisions to make EU-wide joint clinical assessments voluntary would make proposed legislation on HTA cooperation redundant, says Eurordis.
Plans for EU-wide Joint Clinical assessments will come under scrutiny at an EU council meeting next week.
Pfizer’s Ibrance has won conditional reimbursement in England while more data is gathered to reduce some uncertainty.